One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure ...

Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Sanofi (ENXTPA:SAN) has recently announced it will begin shipping Beyfortus in early Q3 2025. This move aims to support healthcare providers ahead of the RSV season. Sanofi's commitment to increasing ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's ...

Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...

Sanofi (NASDAQ:SNY) will begin shipping Beyfortus (nirsevimab) in early Q3 to ensure widespread availability ahead of the ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...